Form 4: Acrivon Therapeutics' Chief Medical Officer Granted Stock Options
SEC Form 4 Filing
Jean-Marie Cuillerot, Chief Medical Officer of Acrivon Therapeutics, received stock options for 78,078 shares on March 1, 2025.
Summary
- On March 1, 2025, Jean-Marie Cuillerot, the Chief Medical Officer of Acrivon Therapeutics, Inc., was granted stock options to purchase 78,078 shares of common stock.
- The exercise price of these options is $5.31 per share.
- The options vest over time, with 25% vesting on March 1, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is a neutral event.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel like the Chief Medical Officer.
Stakeholder Impact
- The stock option grant aligns the interests of the Chief Medical Officer with those of the shareholders.
- Employees may be motivated by the potential for equity ownership.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of the stock option grant. |
| 03/01/2026 | Date when 25% of the stock options vest. |
| 02/28/2035 | Expiration date of the stock options. |
| 03/04/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.